---
trial_id: 310
discovery_date: 2022-04-02 17:30:16.008202
date: 2022-04-02 17:30:16.008202
title: "A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects..."
summary: |
  <p>EudraCT Number: 2004-000337-12<br />Sponsor Protocol Number: 24810<br />Sponsor Name: Serono International SA<br />Start Date: 2004-07-23<br />Medical condition: MS with 2 or more relapses within the last 2 years <br />Disease: <br />Version: 7.0<br />SOC Term: <br />Classification Code: 10028245<br />Term: <br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000337-12/HU">HU</a> (Completed)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000337-12'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2004-000337-12<br />Sponsor Protocol Number: 24810<br />Sponsor Name: Serono International SA<br />Start Date: 2004-07-23<br />Medical condition: MS with 2 or more relapses within the last 2 years <br />Disease: <br />Version: 7.0<br />SOC Term: <br />Classification Code: 10028245<br />Term: <br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000337-12/HU">HU</a> (Completed)</p>